EUCTR2011-004589-14-GB进行中（未招募）1 期
A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough
Respicopea Limited0 个研究点目标入组 288 人开始时间: 2012年4月3日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 288
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female aged 18 to 75 years
- •2. Confirmed diagnosis of a persistent cough as per Section 4.2 Definition of Terms
- •3. Leicester Cough Questionnaire score of = 17 at baseline
- •4. FEV1 = 70% of predicted normal, at screening. See protocol Appendix 4 for formula for calculating predicted values.
- •5. Willing to use effective contraception for the duration of the study. Female subjects who are neither surgically sterilized nor post menopausal (defined as no menses for one year or an FSH value >40 mIU/L) will be required to use two methods throughout the study and for 30 days after. Besides abstinence the following contraceptive methods are acceptable: hormonal (e.g. oral, injection, transdermal patch, implant, cervical ring), barrier (e.g. condom or diaphragm with spermicidal agent) or intrauterine device. If hormonal contraceptives are used they must be used from 6 weeks before the first administration of test product. Male subjects must agree to use condoms for the duration of the study and for 30 days after.
- •6. Willing and able to give informed consent and of complying with the trial assessments and any other trial procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or lactating females
- •2. Major surgery within the 30 days preceding the screening visit
- •3. Any serious infections within the 30 days prior to the screening visit
- •4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia uncontrolled diabetes, renal or hepatic disease or psychiatric illness/social situations that would limit compliance with study requirements
- •5. Known hepatitis B or C or human immunodeficiency virus (HIV) or syphilis seropositivity.
- •Note: testing for hepatitis, syphilis or HIV will not be performed as part of the screening procedures.
- •6. A history of serious adverse allergic reaction to any medication
- •7. Treatment with another investigational medicinal product within the 30 days prior to enrolment
- •8. Treatment with:
- •a. Systemic oral steroids within 7 days prior to randomisation at Visit 2
- •b. Theophylline and theophylline-like agents within 7 days prior to randomisation
- •c. Opiates or opioids e.g. codeine, dextromethorphan, within 7 days prior to randomisation
- •d. ACE inhibitors within one month prior to the screening visit
- •9. Depot injection of corticosteroids within 6 weeks of the screening visit
- •10. History suggestive of febrile illness within the last 7 days prior to the screening visit
- •11. Subjects with significant sputum production (defined as more than 5 ml (~one teaspoon)/day on any three days in the screening period)
- •12. Current smokers or past smokers who have a smoking history of >20 pack years or stopped smoking =12 months prior to screening.
- •13. Any pulmonary co-morbidity such as COPD, recurrent lower respiratory tract infections (=2 in the 12 months prior to screening) and bronchiectasis where cough suppression may lead to sputum retention and infection.
- •14. Any pulmonary abnormality on chest X-ray or CT scan performed in the twelve months prior to enrolment indicative of COPD, bronchiectasis etc.
- •15. Subjects diagnosed with asthma who have suffered an exacerbation requiring hospitalisation within 4 weeks prior to screening.
- •16. A history of cancer within the previous five years (excluding carcinoma in situ or nonmelanoma skin cancer treated by surgical excision).
- •17. Uncontrolled hypertension (resting systolic BP >170mmHg or resting diastolic BP >95 mm Hg)
- •18. A corrected QT interval of >470ms for female subjects or of >450ms for male subjects, calculated using the QTcF correction formula, or second degree or higher heart block on an ECG recording, at screening
- •19. Subjects known to have a sensitivity to methylxanthines and related compounds, or known to have exhibited an allergic response or sensitivity to cocoa-based products
- •20. History or presence of alcohol or substance abuse.
研究者
相似试验
进行中（未招募）
1 期
A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Refractory Heel Enthesitis in SpondylarthropathyEUCTR2006-002749-35-FRWyeth Pharmaceuticals France20
进行中（未招募）
不适用
A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Refractory Heel Enthesitis in SpondylarthropathyRefractory heel enthesitis in spondylarthropathy.MedDRA version: 8.1Level: LLTClassification code 10058497Term: EnthesitisEUCTR2006-002749-35-NLWyeth Pharmaceuticals France20
进行中（未招募）
不适用
A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients with Active, Severe and Advanced Axial Ankylosing SpondylitisEUCTR2006-002748-27-DEWyeth Pharmaceuticals France80
进行中（未招募）
1 期
A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Active, Severe and Advanced Axial Ankylosing SpondylitisEUCTR2006-002748-27-FRWyeth Pharmaceuticals France80
进行中（未招募）
不适用
A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients with Active, Severe and Advanced Axial Ankylosing SpondylitisActive, severe and advanced axial ankylosing spondylitisMedDRA version: 8.1Level: LLTClassification code 10048811Term: Bechterew's diseaseEUCTR2006-002748-27-NLWyeth Pharmaceuticals France80